The overarching material developed and investigated comprises AngIV-based compounds, designed to overcome the limitations of native peptides like AngIV, which suffer from poor metabolic stability and inability to cross the BBB due to their size and hydrophilicity
Subscribe to our quarterly drug Trials Updates to keep up with the latest news
Injectable therapeutic peptidesAn adjunct to regenerative medicine and sports performance
Chronic conditions may warrant longer use under specialist supervision, with periodic reassessment of whether the combination is still contributing
PepT1 is a low-affinity ( of 200 M to 15 mM), high-capacity transporter and is known to play a pivotal role in the absorption and distribution of peptidomimetics that include -lactam antibiotics such as cephalosporins and penicillins, angiotensin converting enzyme inhibitor such as zofenopril, fosinopril, benazepril, quinapril, trandolapril, spirapril, cilazapril, ramipril, moexipril, quinaprilat, and perindopril., selected rennin inhibitors, antitumor agents such as bestatin, and dopamine receptor antagonists such as sulpiride (Terada et al
Additional information Technical Specifications
